GT200500196A - Derivados de 4-arilmorfolin-3-ona, su preparacion y su aplicacion en terapeutica - Google Patents

Derivados de 4-arilmorfolin-3-ona, su preparacion y su aplicacion en terapeutica

Info

Publication number
GT200500196A
GT200500196A GT200500196A GT200500196A GT200500196A GT 200500196 A GT200500196 A GT 200500196A GT 200500196 A GT200500196 A GT 200500196A GT 200500196 A GT200500196 A GT 200500196A GT 200500196 A GT200500196 A GT 200500196A
Authority
GT
Guatemala
Prior art keywords
therapeutics
preparation
application
derivatives
arilmorfolin
Prior art date
Application number
GT200500196A
Other languages
English (en)
Inventor
Xavier Emonds-Alt
Vincenzo Proietto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200500196A publication Critical patent/GT200500196A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION TIENE POR OBJETO NUEVOS DERIVADOS DE 4ARILMORFOLIN3ONA DE FORMULA I, SU PREPARACION Y SU APLICACION EN TERAPEUTICA, ESTOS COMPUESTOS PRESENTAN UNA MUY IMPORTANTE AFINIDAD CON LOS RECEPTORES NK2 HUMANOS DE LA NEUROQININA A, ESTOS SON UTILES PARA EL TRATAMIENTO DE LA DEPRESION ASI COMO TRASTORNOS GASTROINTESTINALES.
GT200500196A 2004-07-23 2005-07-20 Derivados de 4-arilmorfolin-3-ona, su preparacion y su aplicacion en terapeutica GT200500196A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0408222A FR2873373B1 (fr) 2004-07-23 2004-07-23 Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
GT200500196A true GT200500196A (es) 2006-03-02

Family

ID=34951659

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500196A GT200500196A (es) 2004-07-23 2005-07-20 Derivados de 4-arilmorfolin-3-ona, su preparacion y su aplicacion en terapeutica

Country Status (30)

Country Link
US (1) US7521449B2 (es)
EP (1) EP1773823B1 (es)
JP (1) JP4812759B2 (es)
KR (1) KR20070034066A (es)
CN (1) CN101006084B (es)
AR (1) AR050262A1 (es)
AU (1) AU2005276352A1 (es)
BR (1) BRPI0513581A (es)
CA (1) CA2573446A1 (es)
CR (1) CR8843A (es)
EA (1) EA011035B1 (es)
EC (1) ECSP077181A (es)
FR (1) FR2873373B1 (es)
GT (1) GT200500196A (es)
HK (1) HK1107340A1 (es)
HN (1) HN2005000380A (es)
IL (1) IL180484A0 (es)
MA (1) MA28741B1 (es)
MX (1) MX2007000814A (es)
MY (1) MY142757A (es)
NO (1) NO20071020L (es)
PA (1) PA8640101A1 (es)
PE (1) PE20060553A1 (es)
SV (1) SV2006002176A (es)
TN (1) TNSN06438A1 (es)
TW (1) TW200603800A (es)
UA (1) UA86082C2 (es)
UY (1) UY29022A1 (es)
WO (1) WO2006021654A1 (es)
ZA (1) ZA200700603B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2912058A1 (fr) * 2007-02-07 2008-08-08 Sanofi Aventis Sa Utilisation d'un compose antagoniste des recepteurs nk2 de la neurokinine a pour la preparation de medicaments utiles pour la prevention et le traitement des dysfonctions sexuelles
WO2015200594A2 (en) 2014-06-25 2015-12-30 Emory University Methods of managing conditioned fear with neurokinin receptor antagonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751654B1 (fr) * 1996-07-26 1998-10-23 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2729954B1 (fr) * 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2738819B1 (fr) * 1995-09-14 1997-12-05 Sanofi Sa Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
HU224225B1 (hu) * 1995-12-01 2005-06-28 Sankyo Co. Ltd. Tachikinin receptor antagonista hatású heterociklusos vegyületek, ezek előállítási eljárása és alkalmazásuk gyógyszerkészítmények előállítására
GB9601680D0 (en) * 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents
WO1999028307A1 (fr) * 1997-12-04 1999-06-10 Sankyo Company, Limited Derives heterocycliques alicycliques acyles
JPH11240880A (ja) * 1997-12-04 1999-09-07 Sankyo Co Ltd 脂環式アシル化複素環誘導体
GB9812037D0 (en) * 1998-06-04 1998-07-29 Pfizer Ltd Piperidones
FR2789390B3 (fr) * 1999-02-10 2001-03-09 Sanofi Sa Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
FR2791346B3 (fr) * 1999-03-25 2001-04-27 Sanofi Sa Nouveaux derives de morpholine, procede pour leur preparation et compositions pharmaceutiques les contenant
CA2393672A1 (en) * 1999-12-17 2001-06-21 Schering Corporation Selective neurokinin antagonists
FR2824828B1 (fr) * 2001-05-21 2005-05-20 Sanofi Synthelabo Nouveaux derives de piperidinecarboxamide, un procede pour leur preparation et les compositions pharmaceutiques les contenant
GB0130261D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Lactams as tachykinin antagonists

Also Published As

Publication number Publication date
MA28741B1 (fr) 2007-07-02
US20070142349A1 (en) 2007-06-21
AU2005276352A1 (en) 2006-03-02
WO2006021654A1 (fr) 2006-03-02
HN2005000380A (es) 2009-05-14
EA011035B1 (ru) 2008-12-30
KR20070034066A (ko) 2007-03-27
CA2573446A1 (fr) 2006-03-02
CR8843A (es) 2007-08-28
BRPI0513581A (pt) 2008-05-13
EP1773823A1 (fr) 2007-04-18
UY29022A1 (es) 2006-02-24
PE20060553A1 (es) 2006-07-04
ZA200700603B (en) 2008-10-29
JP4812759B2 (ja) 2011-11-09
EP1773823B1 (fr) 2013-08-21
TW200603800A (en) 2006-02-01
ECSP077181A (es) 2007-02-28
AR050262A1 (es) 2006-10-11
FR2873373A1 (fr) 2006-01-27
CN101006084B (zh) 2010-09-08
JP2008507497A (ja) 2008-03-13
CN101006084A (zh) 2007-07-25
MX2007000814A (es) 2007-04-02
IL180484A0 (en) 2007-06-03
TNSN06438A1 (fr) 2008-02-22
FR2873373B1 (fr) 2006-09-08
EA200700098A1 (ru) 2007-06-29
WO2006021654A8 (fr) 2007-05-24
NO20071020L (no) 2007-02-22
MY142757A (en) 2010-12-31
HK1107340A1 (en) 2008-04-03
US7521449B2 (en) 2009-04-21
SV2006002176A (es) 2006-01-13
PA8640101A1 (es) 2006-03-24
UA86082C2 (ru) 2009-03-25

Similar Documents

Publication Publication Date Title
HN2005000795A (es) Pirimidinas como antagonistas del receptor de prostaglandina d2
ECSP067121A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
UY32225A (es) Antagonistas de cicloalcano[b]azaindol de los receptores de la prostaglandina d2
ECSP067120A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
CR10138A (es) 1h indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina
NI201100084A (es) Antagonistas del receptor de orexina de isonicotinamida.
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
ECSP077296A (es) Fenilaminotiazoles sustituidos y su uso
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
ECSP066991A (es) 3-(4-heteroarilciclohexilamino)ciclopentanocarboxamidas como moduladores de receptores de quimiocinas
UY30052A1 (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
UY29478A1 (es) Compuestos heteroaromaticos acilaminobiciclicos y sus usos
ECSP109923A (es) Bromhidrato de bupropion y aplicaciones terapéuticas
CR20110294A (es) Piperidina espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico
CY1118583T1 (el) Σταθερες δοσολογικες μορφες ανθελονοσιακων σπιρο και δισπιρο 1,2,4-τριοξολανιων
DE602005007765D1 (de) Neue indol- oder benzimidazol-derivate
UY30046A1 (es) Nuevos derivados de furopirimidina acíclicos sustitiudos y su uso
ECSP109961A (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica
PA8658001A1 (es) Sulfonamido-macrociclos y sus sales, una composicion farmaceutica que comprende estos compuestos, un metodo de preparacion y el uso de los mismos
DOP2011000166A (es) Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparacion y uso terapeutico
ECSP10010379A (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina
CR9733A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
CR9734A (es) Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6